CADENCE’s National Cardiovascular Clinical Trials Network brings together existing cardiovascular (CV) clinical trial units at the National University Heart Centre Singapore (NUHCS), National Heart Centre Singapore (NHCS) and Tan Tock Seng Hospital (TTSH) to function as one to support mechanistic early-phase multi-site clinical trials across Singapore.
This platform will partner with other coordinating bodies being developed by the Singapore Clinical Research Institute (SCRI) across all the clinical domains.
In addition, the National CV Biostatistics and Bioinformatics Unit established will partner with other business units within the Consortium for Clinical Research and Innovation, Singapore (CRIS) to scale-up biostatistics and bioinformatics capabilities at the national level.
Through this platform, we aim to:
Provide a centralised platform for the design, implementation, and conduct of clinical trials in cardiovascular medicine
Streamline the regulatory and administrative processes involved in conducting clinical trials
Facilitate collaboration and partnerships among researchers, clinicians, and industry leaders in cardiovascular medicine
Through this network, the research community will have a unified platform to conduct more efficient and effective clinical trials, leading to quicker development and approval of new cardiovascular therapies and interventions. This would ultimately improve patient outcomes and contribute to the prevention, diagnosis, and treatment of cardiovascular diseases.
Cancer treatments, including chemotherapies and radiotherapies, increase the risk of cardiovascular disease.
Among many cancer survivors, the risk of mortality from cardiac disease may be higher than the cancer itself. Consequently, there has been increasing interest in detecting cancer therapy-associated cardiac dysfunction (CTRCD) early so that the patients can receive appropriate heart failure treatment.
As a result, the European Society of Cardiology recently released the first-ever guidelines on cardio-oncology, intended to guide clinicians to better recognise and treat patients with CTRCD.
Through this Use Case, CADENCE aims to:
Evaluate the accuracy, cost-effectiveness, and patient preference of an AI-echo guided strategy as compared to standard echocardiography in the detection of CTRCD.
Demonstrate earlier detection of CTRCD using an AI-echo guided strategy as compared to a standard echocardiography strategy in breast cancer and lymphoma patients receiving cardiotoxic chemotherapy.
This use case is led by: